We need more data on who’s getting Paxlovid

Last week, I shared a new page from the Department of Health and Human Services (HHS), reporting statistics on COVID-19 therapeutic distribution in the U.S. The new dataset is a helpful step, but it falls far short of the information we actually need to examine who has access to COVID-19 treatments (particularly Paxlovid) and address potential health equity issues.

Read More

Interpreting limited data in our undercounted surge

There’s no sugarcoating it: we are in an extremely confusing and frustrating phase of the pandemic. We see the rising (yet undercounted) case numbers, we hear from friends and family members who have recently tested positive. And yet the CDC’s official COVID-19 guidance is still based on a mostly-green map, while local leaders refuse to reinstate mask mandates or other safety measures.

Read More

Seroprevalence, incomplete data in the wake of the Omicron wave

More than half of Americans have some antibodies from a recent coronavirus infection, according to a new CDC report. The study was published Tuesday in the CDC’s Morbidity and Mortality Weekly Report (MMWR), accompanied by a press conference and other fanfare. To me, this report (and its publicity) reflects the CDC’s current lack of urgency around addressing the pandemic and its continued impacts.

Read More

CDC launches new pandemic forecasting center

This week, the CDC introduced a new team focused on modeling infectious diseases, called the Center for Forecasting and Outbreak Analytics (or CFA). The agency aims to hire about 100 scientists and communicators for the center; they’ll currently focus on COVID-19, but will expand to other diseases in the future.

Read More